Next Article in Journal
The Impact of the COVID-19 Pandemic on Childhood Obesity and Lifestyle—A Report from Italy
Next Article in Special Issue
Improving Functioning of Children Birth to Five with Emotional and Behavioral Problems: The Role of Comprehensive Mental Health Services and Supports
Previous Article in Journal
Predictors of Umbilical Venous Catheter Misalignment
Previous Article in Special Issue
Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports

1
Struttura Complessa di Cardiologia-UTIC-Emodinamica, Azienda Ospedaliero-Universitaria di Cagliari, 09042 Monserrato, Cagliari, Italy
2
Pronto Soccorso ed OBI, Azienda Ospedaliero-Universitaria di Cagliari, 09042 Monserrato, Cagliari, Italy
3
Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Sardinia, Italy
4
School of Medicine, University College of Dublin, D04 V1W8 Dublin, Ireland
5
Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland
6
Children’s Health Ireland at Crumlin, D12 N512 Dublin, Ireland
*
Author to whom correspondence should be addressed.
Pediatr. Rep. 2022, 14(4), 401-409; https://doi.org/10.3390/pediatric14040048
Submission received: 6 August 2022 / Revised: 11 September 2022 / Accepted: 20 September 2022 / Published: 26 September 2022
(This article belongs to the Special Issue Feature Papers in Pediatric Reports)

Abstract

One of the most powerful weapons against COVID-19 is vaccines. After the worldwide spread of the disease, m-RNA vaccines were authorized not only in adult patients, but also in children and adolescents aged 12–18. Since then, alarming reports of cases of myocarditis and/or pericarditis have been noted, primarily involving males after the second vaccine shot. A typical example of myopericarditis occurring in an adolescent a few days after the second shot of an m-RNA vaccine is described here. An in-depth review of all 110 single case reports published up to July 2022 with related features and outcomes is also presented. This is the first extensive analysis focused solely on a significant number of single case reports, which have usually been excluded from systematic reviews and meta-analyses carried out in the field. The analysis presented here confirms that most cases occurred in males after the second injection of an m-RNA vaccine. Cases were mild and responsive to the usual medical treatment. What is newly reported is that not only adolescents, but also older people, especially females, were affected by this adverse event.
Keywords: m-RNA vaccine; COVID-19; myocarditis; pericarditis; adverse event m-RNA vaccine; COVID-19; myocarditis; pericarditis; adverse event

Share and Cite

MDPI and ACS Style

Piras, A.; Melis, G.; Cugusi, L.; Bassareo, P.P. Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports. Pediatr. Rep. 2022, 14, 401-409. https://doi.org/10.3390/pediatric14040048

AMA Style

Piras A, Melis G, Cugusi L, Bassareo PP. Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports. Pediatric Reports. 2022; 14(4):401-409. https://doi.org/10.3390/pediatric14040048

Chicago/Turabian Style

Piras, Alessandra, Giada Melis, Lucia Cugusi, and Pier Paolo Bassareo. 2022. "Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports" Pediatric Reports 14, no. 4: 401-409. https://doi.org/10.3390/pediatric14040048

APA Style

Piras, A., Melis, G., Cugusi, L., & Bassareo, P. P. (2022). Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports. Pediatric Reports, 14(4), 401-409. https://doi.org/10.3390/pediatric14040048

Article Metrics

Back to TopTop